Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
An imbalance between inhibitory and excitatory neurotransmission has been proposed to contribute to altered brain function in individuals with Down syndrome (DS). Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous system and accordingly treatment with GABA-A antagonists can efficiently restore cognitive functions of Ts65Dn mice, a genetic model for DS. However, GABA-A antagonists are also convulsant which preclude their use for therapeutic intervention in DS individuals. Here, we have evaluated safer strategies to release GABAergic inhibition using a GABA-A-benzodiazepine receptor inverse agonist selective for the α5-subtype (α5IA). We demonstrate that α5IA restores learning and memory functions of Ts65Dn mice in the novel-object recognition and in the Morris water maze tasks. Furthermore, we show that following behavioural stimulation, α5IA enhances learning-evoked immediate early gene products in specific brain regions involved in cognition. Importantly, acute and chronic treatments with α5IA do not induce any convulsant or anxiogenic effects that are associated with GABA-A antagonists or non-selective inverse agonists of the GABA-A-benzodiazepine receptors. Finally, chronic treatment with α5IA did not induce histological alterations in the brain, liver and kidney of mice. Our results suggest that non-convulsant α5-selective GABA-A inverse agonists could improve learning and memory deficits in DS individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A mouse model for Down syndrome exhibits learning and behaviour deficits
Reeves, R. H., Irving, N. G., Moran, T. H., Wohn, A., Kitt, C., Sisodia, S. S., Schmidt, C., Bronson, R. T., & Davisson, M. T. (1995) · Nature Genetics · doi:10.1038/ng1095-177 · Cited by 913 · cited 2×
“These mice demonstrate learning and memory defects, as well as synaptic plasticity abnormalities and are widely used for preclinical research on DS (Escorihuela et al., 1995; Kleschevnikov et al., 2004; Reeves et al., 1995).”
Collinson, N., Kuenzi, F. M., Jarolimek, W., Maubach, K. A., Cothliff, R., Sur, C., Smith, A., Otu, F. M., Howell, O., Atack, J. R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-13-05572.2002 · Cited by 628 · cited 4×
“Most studies investigating cognitive-enhancing properties of a 5-specific GABA-A inverse agonists were indeed conducted in rodents trained in the DMTP test (Collinson et al., 2002; Dawson et al., 2006).”
InfluentialKleschevnikov, A. M., Belichenko, P. V., Villar, A. J., Epstein, C. J., Malenka, R. C., & Mobley, W. C. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1766-04.2004 · Cited by 459 · cited 4×
“These mice demonstrate learning and memory defects, as well as synaptic plasticity abnormalities and are widely used for preclinical research on DS (Escorihuela et al., 1995; Kleschevnikov et al., 2004; Reeves et al., 1995).”
InfluentialAltered long-term potentiation in the young and old Ts65Dn mouse, a model for down syndrome
Siarey, R. J., Stoll, J., Rapoport, S. I., & Galdzicki, Z. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00157-3 · Cited by 222 · cited 3×
“In parallel it has been shown recently that a 5 GABA-A inverse agonists, including the drug used in the present study, potentiate LTP in mouse hippocampal slices (Ballard et al., 2009; Dawson et al., 2006) and it can be postulated that these drugs likely have the potential to reverse LTP deficits and concomitantly to i…”
Faure, A., Verret, L., Bozon, B., El Tannir El Tayara, N., Ly, M., Kober, F., Dhenain, M., Rampon, C., & Delatour, B. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.03.009 · Cited by 112 · cited 1×
“Owing to variations in swim speeds between conditions that may impact non-speci-fically on performances, we calculated an unbiased index of spatial learning that is the percentage of the path length spent by mice in the target quadrant (Faure et al., 2009; Janus et al., 2004) (Figure 2(b)).”
Self-citationImpaired conditioned taste aversion learning in APP transgenic mice
Janus, C., Welzl, H., Hanna, A., Lovasic, L., Lane, N., St. George-Hyslop, P., & Westaway, D. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.11.007 · Cited by 51 · cited 1×
“Owing to variations in swim speeds between conditions that may impact non-speci-fically on performances, we calculated an unbiased index of spatial learning that is the percentage of the path length spent by mice in the target quadrant (Faure et al., 2009; Janus et al., 2004) (Figure 2(b)).”
Cited by
Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0143-7 · Cited by 964
Rudolph, U., & Möhler, H. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135947 · Cited by 319
Wu, Z., Guo, Z., Gearing, M., & Chen, G. (2014) · Nature Communications · doi:10.1038/ncomms5159 · Cited by 306
De la Torre, R., De Sola, S., Pons, M., Duchon, A., de Lagran, M. M., Farré, M., Fitó, M., Benejam, B., Langohr, K., Rodriguez, J., et al. (2014) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201300325 · Cited by 286
Self-citationDown syndrome: the brain in trisomic mode
Dierssen, M. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3314 · Cited by 274
Deidda, G., Parrini, M., Naskar, S., Bozarth, I. F., Contestabile, A., & Cancedda, L. (2015) · Nature Medicine · doi:10.1038/nm.3827 · Cited by 268
Ballard, C., Mobley, W., Hardy, J., Williams, G., & Corbett, A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00063-6 · Cited by 264
Neurological phenotypes for Down syndrome across the life span
Lott, I. T. (2012) · Progress in Brain Research · doi:10.1016/b978-0-444-54299-1.00006-6 · Cited by 225
“Development of a GABA-A benzodiazepine receptor inverse agonist that is selective for the a5-subtype receptor appears to eliminate the convulsant propensity while maintaining cognitive restorative properties (Braudeau et al., 2011a,b).”
BackgroundAn epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
Duchon, A., Raveau, M., Chevalier, C., Nalesso, V., Sharp, A. J., & Herault, Y. (2011) · Mammalian Genome · doi:10.1007/s00335-011-9356-0 · Cited by 224
“Based on this observation, several treatments were successfully evaluated in Ts65Dn DS models to restore hippocampusdependent learning (Braudeau et al. 2011; Costa et al. 2008; Fernandez et al. 2007; Moran et al. 2002; Rueda et al. 2008; Salehi et al. 2009).”
Self-citationTrisomy 21 and early brain development
Haydar, T. F., & Reeves, R. H. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.001 · Cited by 200
Xu, R., Brawner, A. T., Li, S., Liu, J.-J., Kim, H., Xue, H., Pang, Z. P., Kim, W.-Y., Hart, R. P., Liu, Y., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.04.014 · Cited by 193
Deidda, G., Bozarth, I. F., & Cancedda, L. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00119 · Cited by 192
Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities
Rueda, N., Flórez, J., & Martínez-Cué, C. (2012) · Neural Plasticity · doi:10.1155/2012/584071 · Cited by 171
The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome
Contestabile, A., Magara, S., & Cancedda, L. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00054 · Cited by 141
Kazuki, Y., Gao, F. J., Li, Y., Moyer, A. J., Devenney, B., Hiramatsu, K., Miyagawa-Tomita, S., Abe, S., Kazuki, K., Kajitani, N., et al. (2020) · eLife · doi:10.7554/elife.56223 · Cited by 125
García-Cerro, S., Martínez, P., Vidal, V., Corrales, A., Flórez, J., Vidal, R., Rueda, N., Arbonés, M. L., & Martínez-Cué, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106572 · Cited by 104
Neumann, F., Gourdain, S., Albac, C., Dekker, A. D., Bui, L. C., Dairou, J., Schmitz-Afonso, I., Hue, N., Rodrigues-Lima, F., Delabar, J. M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20984-z · Cited by 71
Self-citationTreating enhanced GABAergic inhibition in Down syndrome: Use of GABA α5-selective inverse agonists
Martínez-Cué, C., Delatour, B., & Potier, M.-C. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.12.008 · Cited by 58
Self-citationHart, S. J., Visootsak, J., Tamburri, P., Phuong, P., Baumer, N., Hernandez, M., Skotko, B. G., Ochoa‐Lubinoff, C., Liogier D'Ardhuy, X., Kishnani, P. S., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38465 · Cited by 54
“Administration of GABAA α-5 NAMs have been associated with improvements in recognition memory, spatial learning and memory and rescue of hippocampal synaptic plasticity and adult neurogenesis in Ts65Dn mice (Braudeau et al., 2011; Martinez-Cue et al., 2013).”
BackgroundGoeldner, C., Kishnani, P. S., Skotko, B. G., Casero, J. L., Hipp, J. F., Derks, M., Hernandez, M.-C., Khwaja, O., Lennon-Chrimes, S., Noeldeke, J., et al. (2022) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-022-09418-0 · Cited by 48
A transchromosomic rat model with human chromosome 21 shows robust down syndrome features.
Kazuki, Y., Gao, F. J., Yamakawa, M., Hirabayashi, M., Kazuki, K., Kajitani, N., Miyagawa-Tomita, S., Abe, S., Sanbo, M., Hara, H., et al. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.12.015 · Cited by 41
Loss of correlations among proteins in brains of the Ts65Dn mouse model of down syndrome
Ahmed, M. M., Sturgeon, X., Ellison, M., Davisson, M. T., & Gardiner, K. J. (2012) · Journal of Proteome Research · doi:10.1021/pr2011582 · Cited by 39
Reducing Gabaergic Inhibition Restores Cognitive Functions in a Mouse Model of Down Syndrome
Potier, M.-C., Braudeau, J., Dauphinot, L., & Delatour, B. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660185 · Cited by 34
“memory deficits of Ts65Dn mice both in the MWM and the NOR tasks [50].”
MethodSelf-citationAlterations of in vivo CA1 network activity in Dp(16)1Yey Down syndrome model mice
Raveau, M., Polygalov, D., Boehringer, R., Amano, K., Yamakawa, K., & McHugh, T. J. (2018) · eLife · doi:10.7554/elife.31543 · Cited by 32
Carreno, F. R., Collins, G. T., Frazer, A., & Lodge, D. J. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx003 · Cited by 31
“It appears as though selective modulation of the α5-GABAA receptor does not produce any of these adverse effects (Atack et al., 2006; Dawson et al., 2006; Braudeau et al., 2011), although one study suggested that L-655,708 may have some anxiogenic effects in mice (Navarro et al.”
BackgroundTroppoli, T. A., Zanos, P., Georgiou, P., Gould, T. D., Rudolph, U., & Thompson, S. M. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.11.024 · Cited by 29
Brain circuit pathology in Down syndrome: from neurons to neural networks
Bartesaghi, R. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0067 · Cited by 25
Reduced cortical neurotransmitter receptor complex levels in fetal Down syndrome brain
Keihan Falsafi, S., Dierssen, M., Ghafari, M., Pollak, A., & Lubec, G. (2016) · Amino Acids · doi:10.1007/s00726-015-2062-6 · Cited by 13
Metadata
- Authors
- Braudeau, J., Delatour, B., Duchon, A., Pereira, P. L., Dauphinot, L., de Chaumont, F., Olivo-Marin, J.-C., Dodd, R., Hérault, Y., & Potier, M.-C.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2011-06-21
- Volume
- 25
- Issue
- 8
- Pages
- 1030-1042
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2146204807
- Cited by
- 166
- References
- 6
- FWCI
- 16.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.